YOLFTbeta
Prostatype Genomics AB

Prostatype Genomics AB

PROGEN · ST · Healthcare / Diagnostics & Research

0.095SEK+0.00 (+2.15%)

Price History

Full chart

Market Stats

Previous Close0.093
Open0.0932
Day Range0.0898 – 0.0966
52-Week Range0.088 – 2.28
Volume962.30K
Market Cap14.69M
P/E (TTM)0.00
Forward P/E0.00
EPS-0.07
Dividend Yield0.00%
Beta1.40
50-Day Avg0.1403
200-Day Avg0.6276

About

Prostatype Genomics AB (publ) manufactures, markets, and sells prognostic gene tests. The company offers a Prostatype Test System that combines gene expression information with used clinical parameters, such as PSA, gleason score, RTqPCR kit, patient database and algorithms, Prostatype Web System (PWS), and tumor stage, as well as calculates the P-score. Its test is based on a database containing prostate cancer patients; and provides decision support for patients and doctors when making a treatment decision. The company was incorporated in 2007 and is headquartered in Nacka, Sweden.

Company Details

  • SectorHealthcare
  • IndustryDiagnostics & Research
  • CEOMr. Fredrik Rickman
  • Employees7
  • HeadquartersAugustendalsvägen 20, Nacka, Sweden, 131 52, Sweden
  • Websitehttps://www.prostatypegenomics.com

Leadership

  • Mr. Fredrik RickmanCEO & MD
  • Mr. Anders KochChief Financial Officer · b. 1973
  • George SkinnerVice President Commercial operations
  • Ms. Emelie BerglundChief Technology Officer
  • Mr. Nicklas RosendalCommunications Director
  • Joakim SoderinChief Auditor
  • Prof. Gerald L. Andriole Jr., M.D.Global Chief Medical Officer
  • Katarina SjöbergHead of RA and QA
  • Mr. Steven GaalPresident of US operations
  • Mats BergströmSales Director of EMEA

Financials

Income Statement

Currency: SEK2015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue101.50K5.00M161.84K74.08K-683.88K10.00K683.00K1.36M199.00K594.00K
Growth (%)-+4821.69%-96.76%-54.22%---98.54%+6730.00%+98.54%-85.32%+198.49%
Cost of Revenue6.16M4.97M-4.66M6.69M-14.89M-2.50M13.49M-2.37M-1.72M38.21M
Gross Profit-6.06M29.75K4.82M-6.61M--14.20M2.51M683.00K3.73M1.92M-37.62M
Gross Margin-5966.51%0.60%2980.11%-8927.66%--2077.01%25096.42%100.00%274.93%963.82%-6332.66%
Operating Expense5.33M4.66M13.99M1.25M-2.41M18.06M29.37M42.98M42.77M1.46M
Operating Income-11.39M-4.63M-9.16M-7.86M--16.62M-15.55M-28.69M-39.25M-40.85M-39.08M
Operating Margin-11222.45%-92.59%-5662.39%-10609.83%--2430.03%-155482.65%-4200.44%-2894.32%-20529.15%-6579.12%
EBITDA-11.28M-4.52M-8.97M-7.71M--15.76M-15.46M-26.79M-38.02M-37.40M-36.89M
EBITDA Margin-11117.52%-90.46%-5540.26%-10403.65%--2305.20%-154597.82%-3921.82%-2803.83%-18791.96%-6210.94%
Net Income-11.49M-4.75M-9.32M-8.55M--17.41M-15.63M-29.09M-41.44M-41.05M-44.50M
Net Income Margin-11320.24%-95.02%-5757.43%-11535.30%--2545.52%-156297.58%-4258.71%-3055.68%-20628.64%-7492.09%
R&D2.21M2.06M2.52M1.25M-2.41M1.49M3.51M3.23M2.21M1.46M
R&D as % of Total Revenue2177.76%41.17%1558.88%1682.17%-353.02%14881.10%513.57%237.83%1111.06%246.46%
Interest Expense-0156.90K684.24K01.49M81.49K397.00K1.54M1.68M1.61M
Interest Expense % of Total Revenue-0.00%96.95%923.59%-218.52%814.93%58.13%113.57%842.71%271.89%

Balance Sheet

Currency: SEK2015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets4.15M19.71M19.71M17.57M-33.66M40.20M30.95M49.22M41.97M50.86M
Total Liabilities5.47M4.79M13.49M9.03M-5.37M4.30M4.80M24.55M8.50M24.33M
Total Equity-1.32M14.93M6.22M8.55M-28.29M35.91M26.15M24.67M33.47M26.53M
Cash2.55M10.48M8.21M2.69M-15.86M9.83M4.81M2.68M9.42M9.07M
Total Debt3.93M2.09M9.58M6.85M-1.47M1.27M867.00K11.67M67.00K5.30M
Net Debt1.37M-8.39M1.37M4.16M--14.40M-8.56M-3.94M8.98M-9.42M-3.77M

Cash Flow

Currency: SEK2015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow--9.63M-5.71M-9.63M-7.25M-14.71M-16.08M-27.69M-29.14M-44.71M-23.80M
Investing Cash Flow--3.26M-3.26M-3.26M-2.16M-3.26M-2.50M--8.57M-8.36M-13.36M
Financing Cash Flow-7.38M8.10M7.38M15.31M31.14M23.05M18.85M28.91M59.75M36.83M
Capital Expenditure027.00K4.66M3.26M26.20K26.20K2.50M28.56M7.86M258.00K
Free Cash Flow---10.37M-12.89M--14.74M-18.58M-27.69M-37.70M-52.57M-24.06M
FCF to OCF--181.64%133.86%-100.18%115.55%100.00%129.38%117.59%101.08%

Earnings

Report DateMay 27, 2021Jun 30, 2021Sep 30, 2021Feb 24, 2022May 12, 2022Aug 18, 2022Nov 10, 2022Feb 16, 2023May 31, 2023Aug 17, 2023
EPS Estimate----------100.00
EPS Actual-0.26-3.56-5.13-0.36-0.35-0.49-0.42-0.36-0.11-80.00
Surprise---------20.00%
Timing---Pre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-market

Key Statistics & Ratios

Market Cap14.69M
Enterprise Value63.44M
Trailing P/E0.00
Forward P/E0.00
Price / Sales18.24
Price / Book10.26
EPS-0.07
Book Value0.111
Revenue (TTM)805.00K
Gross Profit (TTM)-17.15M
EBITDA-34.16M
Profit Margin0.00%
Operating Margin-4066.96%
Return on Equity-176.16%
Return on Assets-55.91%
Shares Outstanding155.57M
Shares Float540.73M
Beta1.40
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Stock Splits

  • Jul 6, 20268408:3199
  • May 16, 2025585:317
  • Oct 31, 20241:1000
  • Aug 14, 202466:31
  • Dec 8, 2023451:291
  • Apr 24, 20231979:658
  • Jun 29, 20221678:1603